levomepromazine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1752 60-99-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • methotrimeprazine
  • hirnamin
  • levomeprazine
  • levomepromazin
  • levopromazine
  • levoprome
  • levopromethazine
  • levotomin
  • mepromazine
  • levomepromazine
  • levomepromazine maleate
  • methotrimeprazine hydrochloride
  • nozinan
A phenothiazine with pharmacological activity similar to that of both CHLORPROMAZINE and PROMETHAZINE. It has the histamine-antagonist properties of the antihistamines together with CENTRAL NERVOUS SYSTEM effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604)
  • Molecular weight: 328.47
  • Formula: C19H24N2OS
  • CLOGP: 5.03
  • LIPINSKI: 1
  • HAC: 3
  • HDO: 0
  • TPSA: 15.71
  • ALOGS: -4.80
  • ROTB: 5

  • Status: OFM

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.30 g O
0.10 g P

ADMET properties:

PropertyValueReference
BA (Bioavailability) 50 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 12 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 9.90 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 30 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
None FDA IMMUNEX

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Intentional overdose 221.70 23.16 118 5637 62386 50536983
Intentional self-injury 146.49 23.16 65 5690 23047 50576322
Drug interaction 129.49 23.16 135 5620 199486 50399883
Somnolence 128.72 23.16 120 5635 154865 50444504
Toxicity to various agents 120.75 23.16 134 5621 212365 50387004
Extrapyramidal disorder 97.36 23.16 40 5715 11730 50587639
Electrocardiogram QT prolonged 87.65 23.16 61 5694 51825 50547544
Urinary retention 80.32 23.16 45 5710 26145 50573224
Excessive eye blinking 79.44 23.16 19 5736 927 50598442
Neuroleptic malignant syndrome 79.24 23.16 34 5721 11096 50588273
Sopor 63.24 23.16 35 5720 19844 50579525
Suicide attempt 54.63 23.16 46 5709 51686 50547683
Altered state of consciousness 52.26 23.16 32 5723 21878 50577491
Depressed level of consciousness 48.38 23.16 43 5712 51910 50547459
Product use in unapproved indication 44.34 23.16 60 5695 115759 50483610
Drug abuse 41.35 23.16 42 5713 59804 50539565
Hallucination, auditory 40.01 23.16 21 5734 10707 50588662
Aggression 36.02 23.16 25 5730 21091 50578278
Vascular pain 33.86 23.16 9 5746 674 50598695
Asphyxia 33.50 23.16 15 5740 5412 50593957
Hyperprolactinaemia 33.23 23.16 13 5742 3352 50596017
Mental disorder 32.82 23.16 24 5731 21967 50577402
Psychiatric symptom 32.65 23.16 14 5741 4556 50594813
Hypothermia 32.41 23.16 19 5736 11997 50587372
Tension 32.04 23.16 12 5743 2750 50596619
Overdose 31.27 23.16 47 5708 99680 50499689
Illusion 30.83 23.16 9 5746 950 50598419
Diabetic hyperosmolar coma 28.86 23.16 7 5748 362 50599007
Flat affect 28.10 23.16 9 5746 1296 50598073
Bradykinesia 27.90 23.16 12 5743 3931 50595438
Disinhibition 27.81 23.16 8 5747 802 50598567
Muscle rigidity 27.72 23.16 16 5739 9813 50589556
Pulmonary embolism 26.45 23.16 44 5711 101660 50497709
Perforation 26.44 23.16 8 5747 956 50598413
Behaviour disorder 26.37 23.16 10 5745 2370 50596999
Psychomotor retardation 26.17 23.16 11 5744 3407 50595962
Depressed mood 25.55 23.16 25 5730 33998 50565371
Disturbance in attention 25.47 23.16 24 5731 31162 50568207
Galactorrhoea 25.26 23.16 11 5744 3712 50595657
Partial seizures with secondary generalisation 24.56 23.16 6 5749 320 50599049
Blood prolactin increased 23.82 23.16 10 5745 3089 50596280
Antipsychotic drug level increased 23.78 23.16 10 5745 3099 50596270
Schizophrenia 23.45 23.16 13 5742 7384 50591985

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neuroleptic malignant syndrome 140.60 25.42 67 5769 16081 29552610
Drug abuse 132.16 25.42 116 5720 79767 29488924
Intentional self-injury 106.30 25.42 51 5785 12410 29556281
Sopor 82.01 25.42 41 5795 10893 29557798
Toxicity to various agents 79.75 25.42 131 5705 173530 29395161
Extrapyramidal disorder 76.51 25.42 39 5797 10792 29557899
Dystonic tremor 74.39 25.42 15 5821 182 29568509
Acute pulmonary oedema 67.85 25.42 31 5805 6748 29561943
Suicide attempt 67.47 25.42 55 5781 34055 29534636
Blood glucose fluctuation 57.75 25.42 23 5813 3574 29565117
Intestinal haemorrhage 57.61 25.42 22 5814 3057 29565634
Dystonia 57.17 25.42 31 5805 9718 29558973
Intentional overdose 53.83 25.42 51 5785 38477 29530214
Electrocardiogram QT prolonged 48.90 25.42 47 5789 36090 29532601
Wrong patient received product 48.86 25.42 18 5818 2264 29566427
Altered state of consciousness 47.80 25.42 36 5800 19853 29548838
Blood glucose abnormal 46.98 25.42 22 5814 5061 29563630
Restlessness 46.50 25.42 37 5799 22108 29546583
Sudden death 44.16 25.42 30 5806 14080 29554611
Drug interaction 43.59 25.42 110 5726 197275 29371416
Cognitive disorder 42.50 25.42 36 5800 23463 29545228
Parkinsonism 42.27 25.42 23 5813 7255 29561436
Victim of chemical submission 38.43 25.42 7 5829 47 29568644
Gastrointestinal hypermotility 38.03 25.42 8 5828 121 29568570
Rhabdomyolysis 37.87 25.42 53 5783 60755 29507936
Somnolence 37.82 25.42 67 5769 93888 29474803
Blood creatine phosphokinase increased 37.33 25.42 43 5793 40601 29528090
Electrocardiogram QT shortened 36.88 25.42 8 5828 141 29568550
Wrong schedule 36.67 25.42 8 5828 145 29568546
Aggression 33.31 25.42 38 5798 35503 29533188
Drug screen false positive 33.25 25.42 10 5826 670 29568021
Dyspnoea 32.54 25.42 12 5824 326720 29241971
Respiratory depression 31.42 25.42 24 5812 13499 29555192
Urinary incontinence 31.34 25.42 26 5810 16455 29552236
Overdose 30.92 25.42 56 5780 79763 29488928
Schizophrenia 30.69 25.42 18 5818 6547 29562144
Mumps 29.16 25.42 6 5830 81 29568610
Depressed level of consciousness 28.85 25.42 36 5800 36906 29531785
Product administration error 28.10 25.42 23 5813 14287 29554404
Miosis 27.39 25.42 18 5818 7991 29560700
Feelings of worthlessness 27.28 25.42 7 5829 260 29568431
Confusional state 26.83 25.42 70 5766 127807 29440884
Balance disorder 26.27 25.42 34 5802 36136 29532555
Hyperhidrosis 25.91 25.42 46 5790 64494 29504197
Coma 25.46 25.42 35 5801 39415 29529276

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neuroleptic malignant syndrome 213.81 20.09 98 10912 24898 64462824
Intentional overdose 178.87 20.09 137 10873 89807 64397915
Intentional self-injury 158.95 20.09 84 10926 28960 64458762
Extrapyramidal disorder 155.78 20.09 73 10937 19479 64468243
Toxicity to various agents 142.70 20.09 236 10774 363277 64124445
Drug abuse 142.25 20.09 142 10868 132232 64355490
Somnolence 140.26 20.09 173 10837 203472 64284250
Sopor 132.45 20.09 75 10935 29586 64458136
Drug interaction 123.55 20.09 221 10789 361862 64125860
Suicide attempt 117.19 20.09 97 10913 70910 64416812
Electrocardiogram QT prolonged 96.06 20.09 91 10919 79357 64408365
Altered state of consciousness 89.29 20.09 64 10946 37838 64449884
Dystonic tremor 76.55 20.09 15 10995 182 64487540
Aggression 65.69 20.09 58 10952 46174 64441548
Depressed level of consciousness 63.80 20.09 74 10936 81362 64406360
Wrong patient received product 59.97 20.09 23 10987 3739 64483983
Psychiatric symptom 58.03 20.09 26 10984 6247 64481475
Excessive eye blinking 57.52 20.09 17 10993 1243 64486479
Dystonia 51.77 20.09 35 10975 18830 64468892
Acute pulmonary oedema 50.79 20.09 30 10980 12779 64474943
Restlessness 50.79 20.09 47 10963 39738 64447984
Overdose 49.88 20.09 94 10916 159472 64328250
Sudden death 49.77 20.09 35 10975 20061 64467661
Urinary retention 45.90 20.09 49 10961 49152 64438570
Psychomotor hyperactivity 44.97 20.09 29 10981 14422 64473300
Muscle rigidity 42.27 20.09 30 10980 17443 64470279
Blood creatine phosphokinase increased 42.19 20.09 51 10959 58507 64429215
Schizophrenia 41.27 20.09 25 10985 11143 64476579
Substance abuse 40.11 20.09 23 10987 9269 64478453
Rhabdomyolysis 39.08 20.09 62 10948 91664 64396058
Intestinal haemorrhage 39.05 20.09 19 10991 5495 64482227
Hypothermia 38.84 20.09 30 10980 19826 64467896
Parkinsonism 37.85 20.09 26 10984 14347 64473375
Salivary hypersecretion 34.50 20.09 23 10987 12090 64475632
Agitation 33.94 20.09 57 10953 88310 64399412
Akathisia 33.13 20.09 22 10988 11488 64476234
Wrong schedule 31.90 20.09 8 11002 314 64487408
Coma 31.65 20.09 55 10955 87560 64400162
Depressed mood 31.64 20.09 37 10973 40975 64446747
Drug screen false positive 30.76 20.09 10 11000 1002 64486720
Cognitive disorder 28.82 20.09 41 10969 55046 64432676
Vascular pain 28.55 20.09 9 11001 817 64486905
Sedation 28.06 20.09 35 10975 41427 64446295
Behaviour disorder 27.53 20.09 14 10996 4448 64483274
Asphyxia 26.85 20.09 18 10992 9548 64478174
Blood glucose fluctuation 26.40 20.09 15 10995 5940 64481782
Rash 26.04 20.09 24 10986 458525 64029197
Mental disorder 25.83 20.09 27 10983 26418 64461304
Hyperprolactinaemia 25.80 20.09 13 10997 4052 64483670
Colitis ischaemic 25.65 20.09 20 10990 13394 64474328
Blood glucose abnormal 25.56 20.09 17 10993 8896 64478826
Product use in unapproved indication 25.45 20.09 77 10933 176541 64311181
Pain 24.89 20.09 35 10975 553476 63934246
Feelings of worthlessness 24.13 20.09 7 11003 479 64487243
Hallucination 24.11 20.09 44 10966 72744 64414978
Pneumonia aspiration 23.78 20.09 39 10971 59232 64428490
Abnormal behaviour 23.74 20.09 29 10981 33593 64454129
Obsessive-compulsive disorder 23.72 20.09 13 10997 4805 64482917
Disturbance in attention 23.62 20.09 32 10978 41042 64446680
Asthenia 23.60 20.09 23 10987 428021 64059701
Tension 23.55 20.09 12 10998 3828 64483894
Poisoning deliberate 23.45 20.09 19 10991 13439 64474283
Neuroleptic-induced deficit syndrome 23.07 20.09 4 11006 23 64487699
Illusion 22.90 20.09 9 11001 1561 64486161
Victim of chemical submission 22.63 20.09 6 11004 294 64487428
Galactorrhoea 22.52 20.09 11 10999 3208 64484514
Bradykinesia 22.49 20.09 14 10996 6546 64481176
Mania 22.26 20.09 20 10990 16266 64471456
Cough 22.15 20.09 12 10998 302136 64185586
Perforation 21.87 20.09 8 11002 1140 64486582
Ileus paralytic 21.63 20.09 15 10995 8400 64479322
Confusional state 21.58 20.09 95 10915 261049 64226673
Diabetic hyperosmolar coma 21.46 20.09 7 11003 709 64487013
Flat affect 21.44 20.09 9 11001 1848 64485874
Hyperhidrosis 21.42 20.09 58 10952 124862 64362860
Respiratory depression 21.24 20.09 23 10987 23420 64464302
Arthralgia 20.84 20.09 27 10983 442233 64045489
Chemical poisoning 20.81 20.09 5 11005 164 64487558
Dyskinesia 20.14 20.09 29 10981 39359 64448363

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N05AA02 NERVOUS SYSTEM
PSYCHOLEPTICS
ANTIPSYCHOTICS
Phenothiazines with aliphatic side-chain
MeSH PA D000700 Analgesics
MeSH PA D018712 Analgesics, Non-Narcotic
MeSH PA D014150 Antipsychotic Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D015259 Dopamine Agents
MeSH PA D018492 Dopamine Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D018689 Sensory System Agents
MeSH PA D014149 Tranquilizing Agents
CHEBI has role CHEBI:37930 phenothiazine antipsychotic drugs
CHEBI has role CHEBI:48279 serotonin antagonists
CHEBI has role CHEBI:48561 dopaminergic antagonists
CHEBI has role CHEBI:48873 acetylcholine receptor antagonist
CHEBI has role CHEBI:76779 post-proline endopeptidase inhibitors
CHEBI has role CHEBI:149553 anticoronaviral drug

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Alcoholism contraindication 7200002
Organophosphate poisoning contraindication 8260003
Weight gain finding contraindication 8943002
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Senile dementia contraindication 15662003
Chronic disease of respiratory system contraindication 17097001
Myocardial infarction contraindication 22298006 DOID:5844
Glaucoma contraindication 23986001 DOID:1686
Orthostatic hypotension contraindication 28651003
Torsades de pointes contraindication 31722008
Parkinsonism contraindication 32798002
Conduction disorder of the heart contraindication 44808001
Chronic heart failure contraindication 48447003
Bradycardia contraindication 48867003
Extrapyramidal disease contraindication 76349003
Hyperglycemia contraindication 80394007 DOID:4195
Epilepsy contraindication 84757009 DOID:1826
Leukopenia contraindication 84828003 DOID:615
Stupor contraindication 89458003
Tardive dyskinesia contraindication 102449007
Prolonged QT interval contraindication 111975006
Acute disease of cardiovascular system contraindication 128487001
Angina pectoris contraindication 194828000
Disease of liver contraindication 235856003 DOID:409
Metabolic syndrome X contraindication 237602007 DOID:14221
Hyperprolactinemia contraindication 237662005 DOID:12700
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Anemia contraindication 271737000 DOID:2355
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Coma contraindication 371632003
At risk for aspiration contraindication 371736008
Visual impairment contraindication 397540003
Breastfeeding (mother) contraindication 413712001
Myocardial ischemia contraindication 414795007 DOID:3393
Obesity contraindication 414916001 DOID:9970
Congenital long QT syndrome contraindication 442917000
Carcinoma of female breast contraindication 447782002




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.92 Basic
pKa2 4.55 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Histamine H1 receptor GPCR Ki 9.24 PDSP
Pleiotropic ABC efflux transporter of multiple drugs Transporter IC50 5.02 CHEMBL

External reference:

IDSource
4018915 VUID
N0000147208 NUI
D00403 KEGG_DRUG
4018915 VANDF
CHEBI:6838 CHEBI
CHEMBL1764 ChEMBL_ID
C017901 MESH_SUPPLEMENTAL_RECORD_UI
7603 IUPHAR_LIGAND_ID
705 INN_ID
7104-38-3 SECONDARY_CAS_RN
DB01403 DRUGBANK_ID
9G0LAW7ATQ UNII
72287 PUBCHEM_CID
160372 RXNORM
1834 MMSL
5078 MMSL
d00814 MMSL
001581 NDDF
004134 NDDF
005070 NDDF
387509007 SNOMEDCT_US
395790003 SNOMEDCT_US
57911003 SNOMEDCT_US
89029005 SNOMEDCT_US
D008728 MESH_DESCRIPTOR_UI
C0025678 UMLSCUI
CHEMBL1725730 ChEMBL_ID
CHEMBL2104973 ChEMBL_ID

Pharmaceutical products:

None